TABLE 3.

Clinical characteristics, frequency of HHV-8-infected PBMCs, and virus load per positive cell in HHV-8 PCR-positive subjects^a

Groupb	KS status	CD4 count in cells/μl (%)	HIV load (no. of copies/ml)	HIV treatment	KS treatment	Antiherpes treatment	No. of HHV-8-infected cells/106 PBMCs	No. of HHV-8 genomes/106 PBMCs	No. of HHV-8 genomes/infected cellc	No. of HHV-8 genomes/200 μl of plasma	HHV-8 antibody titer
KS subjects
7a	Cutaneous (progressing)	207 (13)	1,041	AZT, ddl, Kaletra	Doxo	ACV	29	169	5.8	832	51,200
7b	Cutaneous (progressing) and oropharyngeal	225 (12)	<500	AZT, ddl, Kaletra	Doxo	ACV	5.4	522	97	51	51,200
8a	Cutaneous (progressing)	732 (29)	2.1 × 106	No	Doxo	No	0.84c	278	331d	ND	25,600
8b	Cutaneous (progressing) and oropharyngeal	342 (21)	6.4 × 105	No	No	No	4.8	826	172	46	25,600
9	Cutaneous (improving)	251 (14)	772	NFV, combivir	Doxo	No	4.5	12	2.7	ND	800
10	No current lesions (cutaneous 2 yr before)	961 (47)	170	IND, combivir	No	No	1.1	210	191	ND	1,600
11	No current lesions (transient oral 2 yr before)	7 (1)	7.3 × 106	AZT, tenofovir, amprenavir	No	No	NS	13	NS	ND	400
12	No current lesions (transient oral 7 yr before)	410 (19)	1.2 × 104	d4T, 3TC, NLF	No	No	18	1,090	61	5.3	3,200
Subjects at risk for KS
13	No KS	296 (29)	Und.	ddl, RTV, NVR, SAQ	No	No	3.3c	592	179c	ND	400

^aAZT, zidovudine; ddl, didanosine; Kaletra, lopinavir/ritonavir; doxo, doxorubicin; ACV, acyclovir; NFV, nelfinavir; Combivir, zidovudine/lamivudine; IND, indinavir; RTV, ritonavir; SAQ, saquinavir; ND, not detected; Und., undetectable; NS, insufficient specimen.

^bFor subjects 7 and 8, specimens were obtained at two time points, 3 and 2 months apart, respectively.

^cMean genomes per infected cell.

^dCalculations based on 1 dilution only.